Future research should prioritize large validation cohorts and explore combinatorial biomarker approaches that integrate GPC3 with other molecular and immune markers to refine decision-making and improve outcomes in advanced HCC. The gene discussed is GPC3; the disease is hepatocellular carcinoma.